Imurel (Iv) (Azathioprine)

Azathioprine is a prodrug that is converted to 6‑mercaptopurine inside cells. This metabolite interferes with purine synthesis, which is essential for DNA replication. By limiting DNA production, the drug reduces the proliferation of T and B lymphocytes, thereby dampening the immune response.

The dosing regimen for Imurel (Iv) is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should determine the appropriate dose.

Azathioprine is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used during pregnancy only if the potential benefits justify the risks. Limited data are available for breastfeeding; a decision should be made by the prescriber after weighing benefits and potential infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Azathioprine belongs to the antimetabolite class and differs from calcineurin inhibitors such as cyclosporine or tacrolimus, which act on different intracellular pathways. Azathioprine offers oral and intravenous formulations and is often used when long‑term maintenance therapy is needed, but individual response and side‑effect profiles guide the choice of agent.

Imurel (Iv) should be stored at ambient temperature, below 25 °C. Keep the solution in its original packaging, protect it from light, and avoid exposure to moisture. Do not freeze the product.

Imurel (Iv) is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing clinician, taking into account the patient’s condition, dosage, and tolerance.

The most serious risks include severe bone marrow suppression (pancytopenia), hepatotoxicity, pancreatitis, opportunistic infections, and an increased risk of certain malignancies such as lymphoma. Patients should be monitored regularly for blood counts, liver function, and signs of infection.

Imurel (Iv) is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, in those with severe bone marrow depression, and in individuals with active, uncontrolled infections. Caution is also advised for patients with significant liver disease.